Evolving Therapies in Chronic Lymphocytic Leukemia

EP. 1: Initial Work-up for Chronic Lymphocytic Leukemia

July 30th 2020

EP. 2: Impact of COVID-19 on Management of CLL

July 30th 2020

EP. 3: Advances in Frontline Therapy for CLL

July 30th 2020

EP. 4: Selecting First-Line Therapy for CLL

July 30th 2020

EP. 5: COVID-19 and CLL Treatment Initiation

July 30th 2020

EP. 6: Selecting Frontline Therapy for CLL

July 30th 2020

EP. 7: Frontline Treatment Options in CLL

July 30th 2020

EP. 8: Treating CLL During COVID-19

July 30th 2020

EP. 9: Current Role for Chemoimmunotherapy in CLL

July 30th 2020

EP. 10: BTK Inhibitors in CLL: Ibrutinib

July 30th 2020

EP. 11: Telemedicine for Patients With CLL

July 30th 2020

EP. 12: Therapies in the Pipeline for Frontline CLL

July 30th 2020

EP. 13: Second-Generation BTK Inhibitors in CLL

July 30th 2020

EP. 14: BTK inhibitor With vs Without a CD20-Targeted Antibody

July 30th 2020

EP. 15: Relapsed/Refractory CLL: Treatment Selection

July 30th 2020

EP. 16: Novel Therapies for Relapsed/Refractory CLL

July 30th 2020

EP. 17: Venetoclax and Obinutuzumab in CLL

July 30th 2020

EP. 18: Venetoclax Combinations, Safety and Efficacy

July 30th 2020

EP. 19: Utility of MRD Testing in CLL Management

July 30th 2020

EP. 20: MURANO Trial Update in R/R CLL

July 30th 2020

NEXT PAGE
PREVIOUS PAGE
x